APTAMER GROUP PLC - Full year results for the year ended 30 June 2026

Aptamer grew revenue 28% and cash to £4.4m while racing to convert a £7m pipeline into recurring licensing and royalty income by 2028.

• Revenue up 28%: FY26 group revenue hit £1.5m (vs £1.2m), including £0.1m initial licensing income from Twist Bioscience and Alphazyme; repeat business from large pharma grew 36%.
• Margins and losses: Gross margin improved from 48% to 53% on in-house manufacturing/automation; adjusted EBITDA loss held at £2.3m (vs £2.2m) despite higher R&D spend.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.